ARCHER 1009 Subset Analysis and LUX-8 Lung: Erlotinib Compared With Dacomitinib or Afatinib

Article Information

DOI 
http://dx.doi.org/10.1177/1559897715588077
Published By 
SAGE Publications
Print ISSN 
1559-8977
Online ISSN 
2155-756X
Copyright & Usage 
© 2015 SAGE Publications

Author Information

  1. Kathy Boltz, PhD
  1. Luis Paz-Ares, MD, PhD
    1. Hospital Universitario Virgen del Rocio, Seville, Spain
  2. Silvia Novello, MD, PhD
    1. San Luigi Hospital, Orbassano, Italy
  3. Glendwood D. Goss, MD
    1. University of Ottawa, Ottawa, Canada
View Full Text

Article usage

AbstractFullPDF
May 20152310
Jun 20152730
Jul 20151000
Aug 20152400
Sep 20159600
Oct 20151532
Nov 201530710
Total50282

Note: Article usage statistics are calculated and reported monthly.

Cited By...

  • No citing articles found.
Back to top

Tools

View Full Page PDF
Citation Tools
Email
ARCHER 1009 Subset Analysis and LUX-8 Lung: Erlotinib Compared With Dacomitinib or Afatinib
Permalink: Copy
Linkedin Share Button del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo StumbleUpon logo

Table of contents

Cited By...

  • No citing articles found.

Keywords

dacomitinib
erlotinib
afatinib
tyrosine kinase inhibitor
non–small cell lung cancer
progression-free survival
ARCHER 1009
LUX-8 Lung
drug therapy
EGFR
squamous cell carcinoma
Oncology Clinical Trials
Head & Neck Cancers